Emergencies, Independence & Hemorrhage (1.23.2026)
Dr. Jack Cush reviews the news and reports from the past two weeks on RheumNow.Com
Read Article
NEJM - Baker’s Cyst
A 63-year-old woman with psoriatic arthritis presented with a 9-month history of pain in the left knee. A nontender, palpable mass was present in the left popliteal fossa, which had a “speech bubble” shape on ultrasonography. https://t.co/7wBnkDoUaX https://t.co/m0AhRnDc4c
Links:
Dr. John Cush @RheumNow( View Tweet )
Turkish study of 128 Psoriatics (62 PSO, 66 PsA) found more periodontitis in PsA vs PSO (47% vs 31%; P=.058). Signif. higher levels of Dz activity seen for PSO (CPDAI: OR 1.38; P = .001) & enthesitis (MASES: OR 1.39; P < .001) if periodontitis present in PsA patients. https://t.co/d8OfarFWeG
Dr. John Cush @RheumNow( View Tweet )
French Retrospective study (2011-22) of 36129 adult psoriasis pts on biologics who recv antibiotics (9366/26% @ baseline, 61% during FU). Abx treatment assoc w/ 12% greater risk biologic D/C (HR 1.12); more for multiple Abx courses (HR 1.29; 95% CI, 1.24-1.35) https://t.co/2Jv5xCibyd
Dr. John Cush @RheumNow( View Tweet )
Are JAK Inhibitors Better at Pain Relief in RA?
MedPage Today
Among rheumatoid arthritis (RA) patients responding to upadacitinib (Rinvoq) or adalimumab, those receiving the former had significantly less residual pain with treatment, according to a post-hoc analysis of phase III trial data.
Read Article
German psoriasis registry PsoBest reports on 595 Rx w/ apremilast (417 APR monotherapy). Compared to Ptx Rx w/ other DMARDs/biologic drugs, APR pts higher age, more comorbidities. Nonserious AEs: ineffectiveness (14%), diarrhea (9%), nausea (7%), HA (6%). https://t.co/TviJmM7Fr9 https://t.co/tY89oHgUgV
Dr. John Cush @RheumNow( View Tweet )
Advanced Practitioner Biologic Prescriptions for Psoriasis
Advanced practice clinicians (APCs; nurse practitioners and physician assistants) deliver a large share of US dermatologic care, accounting for 37% of clinicians and 27% of dermatology visits by 2020. A current JAMA https://t.co/3NtntmpSPV
Dr. John Cush @RheumNow( View Tweet )
Spread of Psoriatic Disease from Skin to Joints
Approximately 20-30 % of all people who suffer from psoriasis also develop painful inflammation in their joints over time. If left untreated, PsA can lead to permanent damage to bones and joints. Why the disease progresses was https://t.co/UbGHFASKvc
Dr. John Cush @RheumNow( View Tweet )
ADJUST trial (248 JIA pts w/ Uveitis & inactive >6mos, either continued or weaned off adalimumab. ADA weaning resulted in more flares (68% vs 14%, mostly uveitis) w/ no protection from background DMARD Rx. Restarting ADA was mostly effective. https://t.co/ZWHfPl2UNl https://t.co/Fk1HES2UIc
Dr. John Cush @RheumNow( View Tweet )
New for RheumNow Live 2026!
Get more from RheumNow Live 2026—before the meeting begins.
Introducing Dr. Mike Putman, Pre-Learn Director, bringing you speaker-selected Pre-Learns and concise video summaries released weekly for registered attendees.
🎥 Watch Now: This week’s PsA https://t.co/vv5XP7EMfu
Dr. John Cush @RheumNow( View Tweet )
The 2025 Rheumatology Year in Review
The year 2025 presented numerous advances in rheumatology and related inflammatory and autoimmune disorders ranging from several new groundbreaking FDA approvals/indications, drug developments, game-changing guidelines and practices that will impact patient care for rheumatic diseases.
Read Article
Advanced Practitioner Biologic Prescriptions for Psoriasis
Advanced practice clinicians (APCs; nurse practitioners and physician assistants) deliver a large share of US dermatologic care, accounting for 37% of clinicians and 27% of dermatology visits by 2020. A current JAMA Dermatology reports APC drug spending trends in dermatology, with a focus on
Read Article
Spread of Psoriatic Disease from Skin to Joints
Approximately 20 to 30 percent of all people who suffer from psoriasis also develop painful inflammation in their joints over time. If left untreated, psoriatic arthritis can lead to permanent damage to bones and joints. Why the disease progresses was assessed by researchers from the
Read Article
2026 Resolutions (1.9.2026)
Dr. Cush reviews the news, announcements and journal articles from this past week on RheumNow. More on Variable bendability, a better way to treat RA, and a novel advance for GLP1a in PsA; and 2026 Resolutions!
https://t.co/DgY2trZGKA https://t.co/3ka4SDRnJO
Dr. John Cush @RheumNow( View Tweet )
ADJUST trial (248 JIA pts w/ Uveitis & inactive >6mos, either continued or weaned off adalimumab. ADA weaning resulted in more flares (68% vs 14%, mostly uveitis) w/ no protection from background DMARD Rx. Restarting ADA was mostly effective. https://t.co/ZWHfPl2UNl https://t.co/xodyrbaQOj
Dr. John Cush @RheumNow( View Tweet )
Systematic review of Apremilast in soriasis and Psoriatic Arthritis: 28 RCTs involving 6825 patients. Efficacy ( PASI 75 and ACR 20) observed at APR 30 mg or 20 mg bid (RR > 2) & both doses did not affect CRP levels. GI side effx most common (see figure) https://t.co/YqfaWPvmTm https://t.co/z8PfJqp0CJ
Links:
Dr. John Cush @RheumNow( View Tweet )
GLP-1 Agonist plus IL-17 Inhibition in Obese Psoriatic Arthritis
Lilly announced the topline results from its phase 3b "TOGETHER PsA" trial, showing that the combination use of ixekizumab (Taltz) and tirzepatide (Zepbound) was superior to IXE alone, yielding both significant https://t.co/8fOXWULH7w
Dr. John Cush @RheumNow( View Tweet )
2026 Resolutions (1.9.2026)
Dr. Jack Cush reviews the news, announcements and journal articles from this past week on RheumNow.com. More on Variable bendability, a better way to treat RA, and a novel advance for GLP1a in PsA; and 2026 Resolutions!
Read Article
GLP-1 Agonist plus IL-17 Inhibition in Obese Psoriatic Arthritis
Lilly announced the topline results from its phase 3b "TOGETHER PsA" trial, showing that the combination use of ixekizumab (Taltz) and tirzepatide (Zepbound) was superior to IXE alone, yielding both significant weight loss and ACR50 disease control in adults with active psoriatic arthritis (PsA
Read Article
Best of 2025: 2025 BSR Guideline for Treatment of Axial Spondyloarthritis
The British Society of Rheumatology's 2025 Guidelines for treating axSpa focus on both axial and extra-musculoskeletal issues like uveitis, psoriasis, and IBD. They evaluate the effectiveness and safety of https://t.co/fxFcqy13g7
Dr. John Cush @RheumNow( View Tweet )
Best of 2025: GRAPPA vs. EULAR on Complex/Difficult-to-Manage Psoriatic Arthritis
Following the establishment of formal definitions for Difficult-to-Treat Rheumatoid Arthritis (D2T RA) by EULAR and Difficult-to-Manage axial Spondyloarthritis (D2M axSpA) by ASAS, the “Difficult” https://t.co/hFejdS4sjk
Dr. John Cush @RheumNow( View Tweet )
Best of 2025: 2025 BSR Guideline for Treatment of Axial Spondyloarthritis
Editor's note: This article was originally published April 22, 2025, and is being shared again as part of RheumNow's 'Best of 2025' series as we close out the year. Enjoy!
Read Article
Best of 2025: Variability of Guidelines on the Perioperative Use of DMARDs in Rheumatic Diseases Patients
More effective treatments in patients with rheumatic diseases have resulted in less need for major surgery, yet a substantial number of RMD patients will undergo surgery often in the setting of DMARDs use. A scoping review looked at numerous clinical practice guidelines/recommendations for the
Read Article
Best of 2025: Targeting Obesity in Rheumatic Disease Patients
Sattar et al. has published an informative overview of the effect of obesity on rheumatic and musculoskeletal diseases (RMDs). They estimate that nearly 70% of RMD patients are overweight or obese.
Read Article
Best of 2025: GRAPPA vs. EULAR on Complex/Difficult-to-Manage Psoriatic Arthritis
The “Difficult” framework has now reached PsA. At EULAR 2025, two independent definitions were presented: one by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and another by EULAR. This short review explores the similarities and differences between these definitions
Read ArticleRecent Blogs
Daily Download
Topic Videos
Rx Updates (filtered for Topic)
Therapeutic Updates
Advancing the Treatment Landscape for Pediatric Psoriatic Disease
Sponsored by Johnson & Johnson
Learn more about a treatment offering pediatric patients 6 years and older who also weigh at least 40 kg, and their physicians and adult caregivers, an option that may improve skin clearance for moderate to severe plaque psoriasis or treat active psoriatic arthritis, collectively known as psoriatic disease.
Read Post